epidoxorubicin + docetaxel + cyclophosphamide

A combination regimen containing **epidoxorubicin**, **docetaxel**, and **cyclophosphamide** is an investigational chemotherapeutic protocol for the treatment of breast cancer, primarily metastatic and high-risk operable breast cancer. Epidoxorubicin (also called epirubicin) is an anthracycline topoisomerase II inhibitor that interferes with DNA synthesis and induces apoptosis in rapidly dividing tumor cells. Docetaxel is a taxane class agent that promotes and stabilizes microtubule assembly, thereby inhibiting mitotic cell division. Cyclophosphamide is an alkylating agent that irreversibly binds DNA, preventing cell replication and leading to cell death. This combination is designed to maximize cytotoxic effects by targeting cancer cells through multiple mechanisms. Published trials of similar regimens (using doxorubicin, the parent compound of epidoxorubicin) demonstrate high response rates and manageable toxicity profiles[1][3]. Epidoxorubicin may be used when there is need to reduce cardiotoxicity compared to doxorubicin.

Other names

ddEC + ddTddEC-ddTdose-dense EC-Tdose-dense epirubicin, cyclophosphamide, and paclitaxel